Download presentation
Presentation is loading. Please wait.
1
A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next- Generation Sequencing Assay Roopika Menon, PhD, Judith Müller, PhD, Petra Schneider, PhD, Sotirios Lakis, MD, Kenneth Thress, PhD, Jürgen Wolf, MD, Lukas Heukamp, MB PhD, Johannes M. Heuckmann, PhD, Frank Griesinger, MD, PhD Journal of Thoracic Oncology Volume 11, Issue 9, Pages e105-e107 (September 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 (A) Pleural effusion sample from a patient with lung cancer patient exhibiting an epidermal growth factor receptor gene (EGFR) exon 19 (glycine-leucine-arginine-glycine-alanine motif) deletion. (B) Upon treatment with erlotinib and afatinib, an EGFR T790M resistance mutation developed. Upon progression, the patient was then treated with the third-generation inhibitor osimertinib, and an EGFR C797G resistance mutation eventually developed. Journal of Thoracic Oncology , e105-e107DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
3
Figure 2 Pleural effusion sample from a patient with lung cancer upon treatment with the third-generation inhibitor osimertinib exhibited an epidermal growth factor receptor gene (EGFR) and v-myc avian myelocytomatosis viral oncogene homolog (MYC) amplification. Plot depicting the mean copy number of (A) MYC (blue) on chromosome 8 in the sample and (B) EGFR (blue) on chromosome 7. A distinct peak denotes an amplification in both EGFR and MYC. Chr., chromosome; Mio. BP, million base pairs. Journal of Thoracic Oncology , e105-e107DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.